Biotech company Moderna (NASDAQ: MRNA) has been southbound for most of the year, but the vaccine maker seems to be ending 2022 on a high note. On Dec. 13, the company's shares soared by more than 20% in one day. As is usually the case with biotechs, Moderna had good news from the clinic to thank for that impressive one-day rally (more on that later).

But the company is still facing issues, including a potential drop in sales of its prized coronavirus vaccines. Are Moderna's shares still worth buying right now? Let's find out.

Continue reading

Source Fool.com